Alemtuzumab induced red cell aplasia and other immune cytopenias - not so 'pure'.
Sign Up to like & getrecommendations! Published in 2021 at "Immunotherapy"
DOI: 10.2217/imt-2021-0163
Abstract: We report on the presentation and outcome of a 28-year-old female who developed red cell aplasia following alemtuzumab therapy for relapsing remitting multiple sclerosis. The patient also developed synchronous immune thrombocytopenia and immune neutropenia, but… read more here.
Keywords: red cell; cell aplasia; aplasia immune; induced red ... See more keywords